Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562285 · ClinicalTrials.gov registry record
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 829
- Enrollment target
NCT04562285: Completed study, sponsored by Henry Ford Health System.
NCT04562285 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 829 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04562285 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 829 participants
- Enrollment target
Study Summary
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
Primary Outcome
The study will assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months. The study will use Beckman Coulter anti-Spike IgG assay and Roche anti-Nucleocapsid assay.
Interventions
- DIAGNOSTIC_TEST Serologic immunoassays to SARS-CoV-2 antibodies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2024-06-07 |
What the finished NCT04562285 record still lists
NCT04562285 is an observational study that tracks outcomes without assigning an intervention. The registered 829 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Serologic immunoassays to SARS-CoV-2 antibodies is the first listed.
NCT04562285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04562285 about?
NCT04562285 is a clinical study titled "Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays". The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
What is the current status of trial NCT04562285?
This trial is currently completed. The enrollment target is 829 participants. The study started on 2020-06-23. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT04562285?
The interventions under investigation include: Serologic immunoassays to SARS-CoV-2 antibodies (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04562285?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI